Cancer – AHOD1331: Randomized Phase 3 Study of Brentuximab Vedotin for Newly Diagnosed High-Risk Classical Hodgkin Lymphoma in Children and Young Adults
What is the goal of this study?
This randomized phase III trial studies brentuximab vedotin and combination chemotherapy to see how well they work compared to combination chemotherapy alone in treating children and young adults with stage IIB or stage IIB - IVB Hodgkin lymphoma.
Who can join the study?
This study might be a good fit for children and young adults who:
- Are between 2 and 22 years old
- Have been newly diagnosed with stage IIB with bulk, stage IIB, stage IVA or stage IVB Hodgkin lymphoma
What will happen if my child takes part in this study?
You can read more about this study on clinicaltrials.gov.
Who can I contact for more information?
To learn more, call 206-987-2106 or send us an email.